Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine

Oxley, Kyp L; Hanson, Brett M.; Zani, Ashley; Bishop, Gail A.

doi:10.1007/s00262-021-02914-7

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, B cells can be easily sourced from peripheral blood. Despite encouraging preclinical − and clinical results, the use of B cells as a cellular cancer vaccine requires improvement. We demonstrate that MACE can act as an effective platform to increase the efficacy of a B-cell-based cancer vaccine.…”

Section: Discussionmentioning

confidence: 99%

Polymer Micropatches as B-Cell Engagers

Prakash,

Kumbhojkar,

Gottlieb

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

B cells, despite their several unique functionalities, remain largely untapped for use as an adoptive cell therapy and are limited to in vitro use for antibody production. B cells can be easily sourced, they possess excellent lymphoid-homing capabilities, and they can act as antigen-presenting cells (APCs), offering an alternative to dendritic cells (DCs), which have shown limited efficacy in the clinical setting. Soluble factors such as IL-4 and anti-CD40 antibody can enhance the activation, survival, and antigen-presenting capabilities of B cells; however, it is difficult to attain sufficiently high concentrations of these biologics to stimulate B cells in vivo. Micropatches as Cell Engagers (MACE) are polymeric microparticles, surface functionalized with anti-CD40 and anti-IgM, which can attach to B cells and simultaneously engage multiple B-cell receptors (BCR) and CD40 receptors. Stimulation of these receptors through MACE, unlike free antibodies, enhanced the display of costimulatory molecules on the B-cell surface, increased B-cell viability, and improved antigen presentation by B cells to T cells in vitro. B-cell activation by MACE further synergized with soluble IL-4 and anti-CD40. MACE also elicited T-cell chemokine secretion by B cells. Upon intravenous adoptive transfer, MACE-bound B cells homed to the spleen and lymph nodes, key sites for antigen presentation to T cells. Adoptive transfer of MACE-B cells pulsed with the CD4+ and CD8+ epitopes of ovalbumin significantly delayed tumor progression in a murine subcutaneous EG7-OVA tumor model, demonstrating the functional benefit conferred to B cells by MACE.

show abstract

Section: Discussionmentioning

confidence: 99%

Polymer Micropatches as B-Cell Engagers

Prakash,

Kumbhojkar,

Gottlieb

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Thus, conditioned B-cells upregulated antigen presentation molecules and were able to stimulate CD4 + and CD8 + T-cell activation and to induce T-cell migration in vitro. Mice vaccinated with tumor lysate–Bvac showed the greatest improved overall survival, a reduction in tumor size and an increased time to tumor appearance compared to those injected with tumor peptides–Bvac or with unstimulated naïve B-cells, used as controls [ 82 ]. Between 2018 and 2019, a phase I clinical trial of an immunotherapeutic vaccine based on B-cells and monocytes as antigen-presenting cells (BVAC-B) was underway in HER2-positive advanced gastric cancer patients.…”

Section: B-cell Vaccines: a Possible Route For Cell-based Vaccines?mentioning

confidence: 99%

Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer

Martinis,

Ricci,

Trevisan

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Colorectal cancer represents 10% of all new cancer cases each year and accounts for almost 10% of all cancer deaths. According to the WHO, by 2040 there will be a 60% increase in colorectal cancer cases. These data highlight the need to explore new therapeutic strategies. Classical interventions include surgical resection, chemotherapy and radiotherapy, which are invasive strategies that have many side effects on the patients and greatly affect their quality of life. A great advance in the treatment of this cancer type, as well as of all the others, could be the development of a vaccination strategy preventing the onset, the progression or the relapse of the pathology. In this review, we summarize the main vaccination strategies that are being studied for the treatment of colorectal cancer (CRC) and finally explore the possibility of using B-cells for the development of a new type of vaccine.

show abstract